{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:04:56Z","timestamp":1792109096981,"version":"4.4.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006484","name":"AbbVie Deutschland GmbH & Co KG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejps.2024.106744","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T08:54:43Z","timestamp":1710147283000},"page":"106744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Distribution and suitability of pulmonary surfactants as a vehicle for topically applied antibodies in healthy and SARS-CoV-2 infected rodent lungs"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-607X","authenticated-orcid":false,"given":"Lea-Adriana","family":"Barlang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Deimel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn-Patrick","family":"Mohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Blaurock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Balkema-Buschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Weinbender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Obernolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia M.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Popp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2024.106744_bib0001","article-title":"Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19","author":"Alipour","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejps.2024.106744_bib0002","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1183\/09031936.02.00284902","article-title":"Exogenous surfactant in acute respiratory distress syndrome: more is better","volume":"19","author":"Anzueto","year":"2002","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejps.2024.106744_bib0003","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1106\/B63Y-KRYG-NGP6-HH32","article-title":"Ultrastructure of exogenous surfactants using cryogenic scanning electron microscopy","volume":"15","author":"Banerjee","year":"2001","journal-title":"J. Biomater. Appl."},{"key":"10.1016\/j.ejps.2024.106744_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.acthis.2023.152077","article-title":"SARS-CoV-2 induced changes in the glycosylation pattern in the respiratory tract of Golden Syrian hamsters","volume":"125","author":"Barlang","year":"2023","journal-title":"Acta Histochem"},{"key":"10.1016\/j.ejps.2024.106744_bib0005","article-title":"Characterization of critical parameters using an air-liquid interface model with RPMI 2650 cells for permeability studies of small molecules","author":"Barlang","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejps.2024.106744_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061379","article-title":"FcRn-dependent transcytosis of monoclonal antibody in human nasal epithelial cells in vitro: a prerequisite for a new delivery route for therapy?","volume":"20","author":"Bequignon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2024.106744_bib0007","doi-asserted-by":"crossref","first-page":"15069","DOI":"10.1038\/s41598-022-19222-4","article-title":"Compellingly high SARS-CoV-2 susceptibility of Golden Syrian hamsters suggests multiple zoonotic infections of pet hamsters during the COVID-19 pandemic","volume":"12","author":"Blaurock","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2024.106744_bib0008","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1208\/s12248-012-9369-y","article-title":"Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics","volume":"14","author":"Bumbaca","year":"2012","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2024.106744_bib0009","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1152\/jappl.2001.90.5.1955","article-title":"A rat lung model of instilled liquid transport in the pulmonary airways","volume":"90","author":"Cassidy","year":"2001","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.ejps.2024.106744_bib0010","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1080\/10717544.2019.1618418","article-title":"Biophysical and chemical stability of surfactant\/budesonide and the pulmonary distribution following intra-tracheal administration","volume":"26","author":"Chen","year":"2019","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejps.2024.106744_bib0011","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jconrel.2009.03.019","article-title":"Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery","volume":"137","author":"Chono","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2024.106744_bib0012","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1034\/j.1600-065X.2000.917311.x","article-title":"Collectins and pulmonary innate immunity: collectins and pulmonary innate immunity","volume":"173","author":"Crouch","year":"2000","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejps.2024.106744_bib0013","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF01997612","article-title":"Osmolality and pH of anti-asthmatic drug solutions","volume":"31","author":"Desager","year":"1990","journal-title":"Agents Actions"},{"key":"10.1016\/j.ejps.2024.106744_bib0014","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s41598-020-58248-4","article-title":"In vitro functional and structural characterization of a synthetic clinical pulmonary surfactant with enhanced resistance to inhibition","volume":"10","author":"Echaide","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2024.106744_bib0015","first-page":"211","article-title":"Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone","volume":"129","author":"Eschenbacher","year":"1984","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.ejps.2024.106744_bib0016","first-page":"391","article-title":"Bolus dispersal through the lungs in surfactant replacement therapy","volume":"86","author":"Espinosa","year":"1999","journal-title":"J. Appl. Physiol. Bethesda Md 1985"},{"key":"10.1016\/j.ejps.2024.106744_bib0017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1203\/00006450-199501000-00006","article-title":"Lysis of red blood cells and alveolar epithelial toxicity by therapeutic pulmonary surfactants","volume":"37","author":"Findlay","year":"1995","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ejps.2024.106744_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009705","article-title":"SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney","volume":"17","author":"Francis","year":"2021","journal-title":"PLOS Pathog."},{"key":"10.1016\/j.ejps.2024.106744_bib0019","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/pharmaceutics11030113","article-title":"Strategies to enhance drug absorption via nasal and pulmonary routes","volume":"11","author":"Ghadiri","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2024.106744_bib0020","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2205540","article-title":"A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations","volume":"15","author":"Ghosh","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.ejps.2024.106744_bib0021","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/2230-973X.108959","article-title":"Exploring targeted pulmonary delivery for treatment of lung cancer","volume":"3","author":"Goel","year":"2013","journal-title":"Int. J. Pharm. Investig."},{"key":"10.1016\/j.ejps.2024.106744_bib0022","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/19420862.2018.1556081","article-title":"Exploring the fate of inhaled monoclonal antibody in the lung parenchyma by microdialysis","volume":"11","author":"Guillon","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.ejps.2024.106744_bib0023","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1152\/jappl.1998.85.1.333","article-title":"A theoretical study of surfactant and liquid delivery into the lung","volume":"85","author":"Halpern","year":"1998","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.ejps.2024.106744_bib0024","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1513\/AnnalsATS.201411-507FR","article-title":"The role of surfactant in lung disease and host defense against pulmonary infections","volume":"12","author":"Han","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.ejps.2024.106744_bib0025","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41390-020-0750-8","article-title":"Surfactant replacement therapy: from biological basis to current clinical practice","volume":"88","author":"Hentschel","year":"2020","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ejps.2024.106744_bib0026","doi-asserted-by":"crossref","first-page":"8048","DOI":"10.1039\/C5SM01603G","article-title":"Lung surfactants and different contributions to thin film stability","volume":"11","author":"Hermans","year":"2015","journal-title":"Soft Matter"},{"key":"10.1016\/j.ejps.2024.106744_bib0027","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.4161\/mabs.34454","article-title":"VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations","volume":"6","author":"Herv\u00e9","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.ejps.2024.106744_bib0028","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jconrel.2020.11.042","article-title":"Pulmonary surfactant and drug delivery: vehiculization, release and targeting of surfactant\/tacrolimus formulations","volume":"329","author":"Hidalgo","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2024.106744_bib0029","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.bbamem.2014.02.015","article-title":"Physiological variables affecting surface film formation by native lamellar body-like pulmonary surfactant particles","volume":"1838","author":"Hobi","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejps.2024.106744_bib0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1152\/advan.00029.2010","article-title":"Characteristics of dietary sugars compared with their roles in body metabolism","volume":"34","author":"Kristek","year":"2010","journal-title":"Adv. Physiol. Educ."},{"key":"10.1016\/j.ejps.2024.106744_bib0031","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1007\/s11095-017-2169-4","article-title":"A biocompatible synthetic lung fluid based on human respiratory tract lining fluid composition","volume":"34","author":"Kumar","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2024.106744_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12111014","article-title":"Impact of glycosylation and species origin on the uptake and permeation of IgGs through the Nasal Airway Mucosa","volume":"12","author":"Ladel","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2024.106744_bib0033","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/pharmaceutics12111025","article-title":"Pulmonary delivery of biological drugs","volume":"12","author":"Liang","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2024.106744_bib0034","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1993769","article-title":"Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies","volume":"13","author":"Liu","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/j.ejps.2024.106744_bib0035","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.bpj.2016.06.025","article-title":"Human pulmonary surfactant protein SP-A1 provides maximal efficiency of lung interfacial films","volume":"111","author":"Lopez-Rodriguez","year":"2016","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejps.2024.106744_bib0036","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.bbamem.2009.01.005","article-title":"Kinematic viscosity of therapeutic pulmonary surfactants with added polymers","volume":"1788","author":"Lu","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejps.2024.106744_bib0037","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.bpj.2012.01.049","article-title":"Thermodynamics of phospholipid self-assembly","volume":"102","author":"Marsh","year":"2012","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejps.2024.106744_bib0038","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12890-018-0761-y","article-title":"Effect of surfactant administration on outcomes of adult patients in acute respiratory distress syndrome: a meta-analysis of randomized controlled trials","volume":"19","author":"Meng","year":"2019","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.ejps.2024.106744_bib0039","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejca.2020.01.004","article-title":"Pharmacokinetics\/Pharmacodynamic (PK\/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?","volume":"128","author":"Mir","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejps.2024.106744_bib0040","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4155\/tde-2017-0037","article-title":"Drug delivery to the lungs: challenges and opportunities","volume":"8","author":"Newman","year":"2017","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ejps.2024.106744_bib0041","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1440-1681.2002.03712.x","article-title":"Intratracheal administration of glucocorticoids using surfactant as a vehicle","volume":"29","author":"Nimmo","year":"2002","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.ejps.2024.106744_bib0042","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/MOP.0000000000000751","article-title":"Genetic causes of surfactant protein abnormalities","volume":"31","author":"Nogee","year":"2019","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.ejps.2024.106744_bib0043","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.bbamem.2010.03.008","article-title":"Pulmonary surfactant layers accelerate O2 diffusion through the air-water interface","volume":"1798","author":"Olmeda","year":"2010","journal-title":"Biochim. Biophys. Acta BBA - Biomembr."},{"key":"10.1016\/j.ejps.2024.106744_bib0044","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejps.2024.106744_bib0045","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1007\/s00253-021-11488-4","article-title":"Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections","volume":"105","author":"Parray","year":"2021","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.ejps.2024.106744_bib0046","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12931-020-01603-w","article-title":"Surfactant therapy for COVID-19 related ARDS: a retrospective case\u2013control pilot study","volume":"22","author":"Piva","year":"2021","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejps.2024.106744_bib0047","unstructured":"Regeneron Pharmaceuticals, Inc., 2022. TREATMENT OF MILD TO MODERATE COVID-19 [WWW Document]. URL https:\/\/www.regencov.com\/hcp\/dosing-administration."},{"key":"10.1016\/j.ejps.2024.106744_bib0048","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1038\/s41598-020-60438-z","article-title":"Antibody transcytosis across brain endothelial-like cells occurs nonspecifically and independent of FcRn","volume":"10","author":"Ruano-Salguero","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2024.106744_bib0049","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-020-03268-9","article-title":"Assessment of pulmonary surfactant in COVID-19 patients","volume":"24","author":"Schousboe","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.ejps.2024.106744_bib0050","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1016\/j.bpj.2010.09.039","article-title":"Combined and independent action of proteins SP-B and SP-C in the surface behavior and mechanical stability of pulmonary surfactant films","volume":"99","author":"Sch\u00fcrch","year":"2010","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejps.2024.106744_bib0051","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2023.04.029","article-title":"Neutralisation of SARS-CoV-2 by monoclonal antibody through dual targeting powder formulation","volume":"358","author":"Seow","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2024.106744_bib0052","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1166\/jbn.2008.022","article-title":"Pulmonary surfactant self-assembles into a functional film of defined molecular architecture irrespective of concentration and solvent of the spreading solution: a fluorescence and atomic force microscopy Study","volume":"4","author":"Sherley","year":"2008","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ejps.2024.106744_bib0053","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s10020-020-00162-6","article-title":"Antibody development for preventing the human respiratory syncytial virus pathology","volume":"26","author":"Soto","year":"2020","journal-title":"Mol. Med."},{"key":"10.1016\/j.ejps.2024.106744_bib0054","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0378-3782(13)70008-2","article-title":"Surfactant therapy: past, present and future","volume":"89","author":"Speer","year":"2013","journal-title":"Early Hum. Dev."},{"key":"10.1016\/j.ejps.2024.106744_bib0055","first-page":"88","article-title":"Mechanisms of lung injury induced by SARS-CoV-2 infection","volume":"37","author":"Upadhya","year":"2022","journal-title":"Physiol. Bethesda Md"},{"key":"10.1016\/j.ejps.2024.106744_bib0056","unstructured":"U.S. Food & Drug Administration, 2021a. Coronavirus (COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19 [WWW Document]. URL https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19."},{"key":"10.1016\/j.ejps.2024.106744_bib0057","unstructured":"U.S. Food & Drug Administration, 2021b. FDA authorizes bamlanivimab and etesevimab monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19 [WWW Document]. URL https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-authorizes-bamlanivimab-and-etesevimab-monoclonal-antibody-therapy-post-exposure-prophylaxis."},{"key":"10.1016\/j.ejps.2024.106744_bib0058","unstructured":"U.S. Food & Drug Administration, 2020. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19 [WWW Document]. URL https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19."},{"key":"10.1016\/j.ejps.2024.106744_bib0059","series-title":"An Alternative Model For Efficacy Testing of Exogenous Surfactant Using the Isolated Perfused Rat Lung (IPL)","author":"Walter","year":"2016"},{"key":"10.1016\/j.ejps.2024.106744_bib0060","article-title":"The role of pulmonary surfactants in the treatment of acute respiratory distress syndrome in COVID-19","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106744_bib0061","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10837450.2012.757782","article-title":"Passive lung-targeted drug delivery systems via intravenous administration","volume":"19","author":"Wei","year":"2014","journal-title":"Pharm. Dev. Technol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724000551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T11:02:47Z","timestamp":1715338967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724000551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":61,"alternative-id":["S0928098724000551"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106744","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distribution and suitability of pulmonary surfactants as a vehicle for topically applied antibodies in healthy and SARS-CoV-2 infected rodent lungs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106744"}}